Raymond James Financial
ENGN icon

Raymond James Financial’s enGene Therapeutics ENGN Stock Holding History

Raymond James Financial’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.9K Buy
21,356
+357
+2% +$1.46K ﹤0.01% 5287
2026
Q1 		$143K Buy
20,999
+1,039
+5% +$9.25K ﹤0.01% 4956
2025
Q4 		$180K Buy
19,960
+9,960
+100% +$79.8K ﹤0.01% 4816
2025
Q3 		$68.3K Buy
10,000
+7,932
+384% +$36.2K ﹤0.01% 4792
2025
Q2 		$7.53K Buy
+2,068
New +$7.76K ﹤0.01% 6039

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Raymond James Financial's ENGN Position: Q2 2026 in Review

Raymond James Financial increased its enGene Therapeutics (ENGN) stake by 1.7% in Q2 2026, buying an estimated $1.46K and bringing the position to 21,356 shares worth $36.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5287.

Raymond James Financial first reported a position in ENGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $180K in Q4 2025. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Raymond James Financial held 21,356 shares of enGene Therapeutics worth $36.9K as of Q2 2026.
  • Raymond James Financial bought 357 enGene Therapeutics shares in Q2 2026, an estimated $1.46K.
  • enGene Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #5287 holding.
  • Raymond James Financial first reported a position in enGene Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Raymond James Financial's enGene Therapeutics position peaked at $180K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.